We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Axsome Gets FDA Deficiency Letter for AXS-05 for Major Depressive Disorder
Axsome Gets FDA Deficiency Letter for AXS-05 for Major Depressive Disorder
Axsome Therapeutics has received a deficiency letter from the FDA for its investigational neurological drug AXS-05 (dextromethorphan-bupropion) for major depressive disorder.